Chemweb Events

Kinase 2016: Next Generation Inhibitors May 16-17 2016
Symposium: United Kingdom [in English]

Perturbation of cell signalling through inhibition of kinase enzymes has delivered nearly 30 approved medicines to date. The seventh SCI/RSC symposium on kinase inhibitor design will feature several highly pertinent themes including new approaches and technologies to modulate and measure kinase function as well as diverse medicinal chemistry case studies. The symposium will also draw on the lessons from history to provide insight into the future direction of the field.

Event Location:
BioCity Nottingham
Pennyfoot Street
Nottingham
NG1 1GF
United Kingdom

Organizer:
Helen Gibb (send an email)
Society Of Chemical Industry
14-15 Belgrave Square
London
SW1X 8PS
United Kingdom
Deadlines
Early registration: Friday, May 13, 2016
Posters: Friday, March 18, 2016
Keynote speakers:

Mark Bunnage, Pfizer, USA

Kurt Pike, AstraZeneca, UK

Jon Roffey, Cancer Research Technology, UK

Celine Cano, Northern Institute for Cancer Research, UK

John Caldwell, The Institute of Cancer Research, UK

John Harling, GlaxoSmithKline, UK

Simon Planken, Pfizer, USA

Barry Toure, Novartis, USA

Jason Kettle, AstraZeneca, UK

Phil Harris, GlaxoSmithKline, USA

Duncan Shaw, Novartis, USA

James Crawford, Genentech, USA

Christel Menet, Galapagos, Belgium

Stefan Knapp, Johann Wolfgang Goethe-University, Germany

Session titles:

Kinase drug discovery: past, present, and future

Identifying high quality, potent and selective inhibitors of ATM kinase: discovery of AZD0156

Kinase identification of proximal substrates (KIPS): a novel chemical genetics approach for kinase substrate identification

Roger Griffin Memorial Lecture: Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK)

The ups and downs of IRE1 kinase-ribonuclease allosteric ligands

Protein degradation using PROTACs as a novel approach to silence kinase function

Discovery of the EGFR-T790M mutant inhibitor PF-06747775; irreversible inhibitor design and proteomic profile

Smaller is better: selectivity design for type 2 MELK inhibitors

A retrospective of kinase drug discovery at AstraZeneca: the critical role of institutional medicinal chemistry knowledge in generating new leads

Identification of highly potent and mono-selective RIP1 kinase inhibitors targeting a unique allosteric pocket

PDGFR inhibitors suitable for inhalation as a treatment for lung remodeling in pulmoanary arterial hypertension (PAH)

Discovery of non-covalent BTK inhibitors for the treatment of rheumatoid arthritis and lupus

Filgotinib: a selective JAK1 inhibitor

Design strategies for the development of selective kinase inhibitors

Registration fees and grants:

Early bird fees before Friday 01 April 2016

GB£240 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£125 . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£145 . . . . . . .. . . . . . . . . . .SCI/RSC Subsidised Member*
GB£290 . . . . . . . . . . . . . . . . . Non-Member

Standard fees after Friday 01 April 2016

GB£290 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£150 . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£175 . . . . . . . . . . . . . . . . . SCI/RSC Subsidised Member*
GB£350 . . . . . . . . . . . . . . . . . Non-Member

Sponsors:

Sygnature Discovery